OptiNose, Inc. provided preliminary unaudited earnings guidance for the three-month period ended March 31, 2024. For the period, the company expects to report approximately $14.9 million in net revenue from sales of XHANCE; a loss from operations of approximately $8.1 million; and a net loss of approximately $14.1 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.14 USD | +7.55% |
|
+9.17% | -7.75% |
May. 20 | OptiNose, Inc. announced that it has received $4.68 million in funding | CI |
May. 14 | Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.98% | 154M | |
+47.54% | 765B | |
-6.80% | 354B | |
+19.38% | 331B | |
+8.73% | 299B | |
+18.87% | 248B | |
-1.96% | 219B | |
+11.11% | 216B | |
+4.53% | 164B | |
-2.71% | 162B |
- Stock Market
- Equities
- OPTN Stock
- News OptiNose, Inc.
- OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024